The FDA announced on 2020-10-28 that Teva Pharmaceuticals USA is recalling Mesalamine Delayed-Release Tablets due to failed dissolution specifications. The agency stated the recall was voluntary and initiated by the firm.
How to tell if you have it
- Brand: Teva Pharmaceuticals USA
- Product: Mesalamine Delayed-Release Tablets, USP 1.2 gram, 120 tablets per bottle
- NDC: 0591-2245-22
- Lots: 1342498A (Exp. 12/2020), 1342499A (Exp. 01/2021), 1354638A (Exp. 03/2021), 1354639A, 1358274A, 1358448A, 1364618A, 1369884A (Exp. 05/2021), 1366195A, 1369885A, 1373570A (Exp. 06/2021), 1373571A (Exp. 07/2021), 1388571A (Exp. 01/2022), 1395725A, 1396585A, 1397550A, 1399389A (Exp. 04/2022), 1403885A, 1403886A (Exp. 06/2022)
- Quantity: 133,829 bottles
- Distribution: Nationwide in the U.S. and PR
The hazard
According to the FDA, out-of-specification dissolution results were obtained during stability testing for the recalled Mesalamine tablets.
Context
GovInfoNow's records show Teva Pharmaceuticals USA has 97 other recalls on record since 2013-10-11. Recent brand recalls include a 2022-01-18 recall of Doxylamine Succinate Tablets for failed dissolution risk, a 2022-01-10 recall of Tretinoin Capsules for failed dissolution testing, and a 2022-01-07 recall of Mimvey Tablets due to mislabeling. Other recent recalls of similar products include Teva Metoprolol Succinate Tablets Recall (2026-01-29), Teva Metoprolol Succinate Extended-Release Tablets Recall (2026-01-29), and Teva Recalls Metoprolol Succinate 50 mg Due to Dissolution Failure (2026-01-29).